Clinical Trials Logo

Clinical Trial Summary

This study aims to address the hypothesis that Lorazepam (an anticonvulsant) is as effective when given via the intranasal or buccal route as the intravenous route in terminating convulsions in children.


Clinical Trial Description

Convulsions are common in children. Prompt treatment with an effective anticonvulsant reduces longterm morbidity and mortality. The use of intravenous lorazepam as first line therapy in acute childhood convulsions where venous access has been obtained is widely accepted in developed countries. However, intravenous access can be a problem out of hospital or in small children.

Benzodiazepines such as Lorazepam have long been the mainstay of first line therapy for acute convulsions but there is insufficient clinical evidence as to the optimal mode of administration when venous access has failed. Lorazepam can be given via the intranasal and buccal route offering the potential to be as effective as intravenous lorazepam whilst being easier to administer and avoiding the need for intravenous cannulation.

To date there are no large published studies that have evaluated the efficacy and safety of intranasal or buccal lorazepam compared to intravenous lorazepam in the treatment of acute convulsions. In this study we wish to address the urgent need to obtain randomized controlled data in treating acute convulsions in children using a drug and delivery system that is safe, effective and easy to use in our setting. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00343096
Study type Interventional
Source University of Malawi College of Medicine
Contact
Status Terminated
Phase Phase 3
Start date June 2006
Completion date March 2009

See also
  Status Clinical Trial Phase
Recruiting NCT03883516 - Improving Emergency Management of Status Epilepticus N/A
Recruiting NCT03378687 - A Clinical Study of Children With Status Epilepticus in China N/A
Recruiting NCT00362141 - Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus Phase 2
Recruiting NCT05140265 - De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information
Recruiting NCT04391569 - Randomized Therapy In Status Epilepticus Phase 3
Recruiting NCT06017973 - The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus N/A
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Recruiting NCT05491590 - Patient-reported Outcome After Status Epilepticus
Recruiting NCT04421846 - Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis N/A
Completed NCT02958605 - Smartphone Apps for Pediatric Resuscitation N/A
Completed NCT02239380 - Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan Phase 3
Completed NCT01796574 - Ketogenic Diet for Refractory Status Epilepticus N/A
Completed NCT02381977 - Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment N/A
Completed NCT00004297 - Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus Phase 3
Completed NCT03905798 - LORA-PITA IV General Investigation
Recruiting NCT05591508 - Ketogenic Diet for Status Epilepticus in Children Post Cessation of Convulsive Status Epilepticus N/A
Completed NCT00735527 - Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children Phase 3
Terminated NCT00265616 - Treatment of Refractory Status Epilepticus Phase 3
Enrolling by invitation NCT06403150 - The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus Phase 4
Recruiting NCT05246566 - Assessment of Adults Epidemiological Characteristics of Status Epilepticus in the French West Indies and in French Guiana